Home | Welcome to Contract Pharma   
Last Updated Friday, December 19 2014

Print

Breaking News

September 30, 2014
Increases capacity to label temperature sensitive investigational products  Read More »
September 30, 2014
Transitions molecule into preclinical development for the treatment of endometriosis  Read More »
September 30, 2014
Diversifies drug supply chain services  Read More »
September 30, 2014
Will begin providing dedicated biologics services in the U.S  Read More »
September 30, 2014
Expands capacity to produce APIs for diabetes drugs  Read More »
September 30, 2014
Gains Phase II antiviral candidate  Read More »
September 30, 2014
Increases plasma processing and albumin production capacity to meet growing demand  Read More »
September 29, 2014
Expands gene-editing capabilities  Read More »
September 29, 2014
Gains Phase III AML candidate quizartinib  Read More »
September 29, 2014
Gains drug candidates and a 500,000 compound CNS-focused, small-molecule library  Read More »
September 29, 2014
Expands therapeutic offerings and Asia-Pac reach  Read More »
September 26, 2014
Forms executive committee   Read More »
September 26, 2014
Will sell Captisol-enabled formulation to Merck   Read More »
September 26, 2014
NP-RD20, an R&D style tablet press, and the NP-155 rotary tablet press  Read More »
September 25, 2014
Previously marketed products will enter $200 million U.S. market  Read More »


Receive free Contract Pharma Direct emails
Sign up now to receive the weekly newsletter, and more!

Enter your email address:
Follow Contract Pharma On